• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

ContraFect

edit

ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases.

Recent Milestones

edit

• 
  ContraFect — Hudson Valley Economic Development Corporation, Steven Rockefeller Jr. and Scenic Hudson praise partnership that will build on Yonkers’ downtown revitalization (4/15/13)
  Posted 4/15/13 at 4:22pm via biospace.com
• 
  ContraFect received $2.2M in Series A funding. (10/26/10)
  Posted 10/27/10 at 6:28pm via finsmes.com
• 
  ContraFect received $12M in Series B funding. (10/26/10)
  Posted 10/27/10 at 6:28pm via finsmes.com
• 
  ContraFect added Robert Nowinski as Chairmain, CEO.
  Posted 10/27/10 at 6:28pm
• 
  ContraFect added Julia Gregory as EVP, CFO.
  Posted 9/13/12 at 7:00pm
• 
  ContraFect added Michael Wittekind as Chief Scientific Officer.
  Posted 9/13/12 at 7:00pm

Videos

Screenshots

edit

Sources

1. ContraFect Raises $14.4M in Two Financing Rounds (finsmes.com) [edit]
2. ContraFect Raises $14.4M in Two Financing Rounds (finsmes.com) [edit]
Chinese Group Makes Strategic Investment in Yonkers Biotechnology Company (biospace.com) [edit]